Espicom publishes over 135 reports on companies developing anti-cancer drugs from the largest blue-chip multinational to smaller specialist organisations - and all phases of development from research to launched products.

For each company you can evaluate:
* Summary: At a glance review of agreements, products and R&D pipeline.
* Overview: Background, ownership structure and research techniques they have developed for drug discovery.
* Agreements: Key details of who the company is collaborating with, and on what.
* Product Portfolio: Product monographs, mechanism of action and indications approved and in development.
* R&D Pipeline: Concise summaries of products in research covering status, indication and clinical trials.
* Financials: An analysis of financial performance including P&L, R&D expenditure and funding. Founded on 6th March 1991, SuperGen is an emerging pharmaceutical company dedicated to the acquisition, rapid development and commercialisation of oncology therapies for solid tumours, haematological malignancies and blood disorders. The company seeks to minimise the time, expense and technical risk associated with drug commercialisation by identifying and acquiring pharmaceutical compounds in the later stages of development, rather than committing significant resources to the research phase of drug discovery. Instead of engaging in pure discovery research to obtain lead compounds, SuperGen licenses or acquires rights to compounds typically at the preclinical or early clinical stage of development that have shown efficacy in humans or in a model relevant to a particular clinical disease. SuperGen then seeks to optimise drug performance and to bring products to market.